Money

Found 79,340 articles

• Amneal Reports First Quarter 2023 Financial Results

  5/5/2023

  Amneal Pharmaceuticals, Inc. announced its actual results for the first quarter ended March 31, 2023. “We are very pleased with our strong first quarter results and start to 2023.

• The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook

  5/5/2023

  Global health company The Cigna Group reported strong first quarter 2023 results reflecting growth and focused execution across our diversified portfolio of businesses.

• SI-BONE Announces Pricing of Public Offering of Common Stock - May 05, 2023

  5/5/2023

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $22.00.

• Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering

  5/5/2023

  Zynex, Inc., announced the pricing of its previously announced private offering of $52.5 million aggregate principal amount of 5.00% convertible senior notes due 2026 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - May 05, 2023

  5/5/2023

  4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 05, 2023

  5/5/2023

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.

• Owens & Minor Reports First Quarter 2023 Financial Results

  5/5/2023

  Owens & Minor, Inc. reported financial results for the first quarter ended March 31, 2023.

• ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock - May 05, 2023

  5/5/2023

  ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions.

• Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

  5/4/2023

  Virax Biolabs Group Limited, an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.

• Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

  5/4/2023

  Journey Medical Corporation announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 11, 2023.

• Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11, 2023

  5/4/2023

  Capricor Therapeutics will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023.

• DarioHealth to Report First Quarter 2023 Results on Thursday, May 11th

  5/4/2023

  DarioHealth Corp., a leader in the global digital health market, announced that it would release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time.

• Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

  5/4/2023

  Adagene Inc. announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.

• SIGA Declares Special Cash Dividend of $0.45 Per Share

  5/4/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company.

• IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

  5/4/2023

  IMUNON, Inc. announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023.

• Brain Cancer Canada Awards CAD 50,000 Grant for Innovative Research to Improve Brain Cancer Diagnosis and Treatment

  5/4/2023

  Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.

• Precipio Signs Another HemeScreen™ Customer

  5/4/2023

  Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory.

• Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

  5/4/2023

  Acorda Therapeutics, Inc. will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET.

• NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023

  5/4/2023

  NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m.

• Axcella Reports First Quarter 2023 Financial Results and Provides Business Update

  5/4/2023

  Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2023 and provided a business update.